Table 2.
SNPs showing preferential allelic imbalance in cSCC tumors
| SNP | Location | Gene | Genotype | Location | Allele 1 | Allele 2 | p-value |
|---|---|---|---|---|---|---|---|
| rs1178355 | 18204811 | HDAC9 | G/T | INTRON | 11 | 3 | 0.0325 |
| rs10243618 | 18522740 | HDAC9 | A/G | INTRON | 7 | 1 | 0.0339 |
| rs1726610 | 18630208 | HDAC9 | G/T | INTRON | 16 | 5 | 0.0163 |
| rs801540 | 18672384 | HDAC9 | G/T | INTRON | 8 | 30 | 0.0004* |
| rs1178108 | 18743747 | HDAC9 | A/G | INTRON | 6 | 19 | 0.0093 |
| rs1178112 | 18746213 | HDAC9 | A/G | INTRON | 3 | 13 | 0.0124 |
| rs11764116 | 18800413 | HDAC9 | G/T | INTRON | 11 | 1 | 0.0039 |
| rs12540872 | 18836667 | HDAC9 | G/A | INTRON | 24 | 11 | 0.0280 |
| rs10269422 | 18854601 | HDAC9 | T/A | INTRON | 3 | 12 | 0.0201 |
Allele 1, number of heterozygous tumors showing relative gain of allele 1; Allele 2, number of heterozygous tumors showing relative gain of allele 2; p-values are unadjusted for multiple comparisons testing
*
significant after Bonferroni correction for 108 SNPs.